A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.
Could tweaking methodologies improve amyloid diagnosis and tracking?
Researchers are looking to the eye for a cheap, easy way to detect Alzheimer’s pathology in the brain.
Mutated huntingtin may stow away in synaptic vesicles to sneak from one neuron to another.
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Plenty of genetic risk factors for sporadic ALS are still waiting to be found, according to a new meta-analysis of GWAS data.
Novartis to Partner with Banner Health on ApoE4 Prevention Trial Crenezumab Disappoints in Phase 2, Researchers Remain Hopeful Alzheimer’s Disease: In the Eye of the Patient? References and Thresholds—Amyloid Imaging Protocols Debated at AAIC Anti-Amyloid ...
Heart-healthy foods containing omega-3 fatty acids, like salmon, slash risk of developing ALS by one-third.
The enzyme PARC acts as a survival factor in damaged neurons and cancer cells by targeting a pro-apoptotic protein for destruction.
Novartis Pharmaceuticals Corporation will partner with the Banner Alzheimer's Institute testing experimental preclinical therapies in the upcoming Alzheimer's Prevention Initiative ApoE4 study. The study complements the API ADAD trial.
In fruit flies that model ALS, presynaptic vesicles gather in unusually large clumps, amplifying signaling at the neuromuscular junction. Does this promote disease?
Blocking calcium-dependent protease normalizes lifespan in mouse tauopathy model.
In a large retrospective study, people with the highest plasma levels of an inflammatory protein experienced the greatest decline in reasoning abilities over the next 10 years.
Allosteric γ-secretase modulator binds an extracellular pocket on presenilin, changing the active site.